FDA Grants Breakthrough Therapy Designation to Lilly's Sofetabart Mipitecan for Platinum-Resistant Ovarian Cancer
核心洞察
The U.S. FDA has granted Breakthrough Therapy designation to Eli Lilly's sofetabart mipitecan (搜索) for treating platinum-resistant ovarian cancer (搜索) patients who have received prior bevacizumab and mirvetuximab soravtansine.
Sofetabart mipitecan (搜索) is a novel folate receptor alpha (搜索) antibody-drug conjugate that demonstrated responses across all dose levels and FR⍺ expression levels in Phase 1 trials.
The drug has advanced to Phase 3 FRAmework-01 study, investigating monotherapy for platinum-resistant disease and combination therapy with bevacizumab for platinum-sensitive ovarian cancer (搜索).
Eli Lilly and Company announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation to sofetabart mipitecan (搜索) (LY4170156) for treating adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer (搜索) who have received prior bevacizumab and mirvetuximab soravtansine, if eligible. The designation aims to expedite development and review of drugs intended to treat serious conditions where preliminary clinical evidence indicates substantial improvement over available therapy.
Addressing Critical Unmet Need
Platinum-resistant ovarian cancer (搜索) represents one of the most challenging settings in gynecologic oncology. According to the source materials, ovarian cancer (搜索) is the fifth leading cause of cancer death among women in the United States. While most patients initially respond to platinum-based chemotherapy, approximately 70% will experience recurrence, leading to progressively shorter remission periods with each subsequent treatment. When cancer recurs during or within six months of platinum therapy—known as platinum-resistant disease—patients face limited treatment options.
"Platinum-resistant ovarian cancer (搜索) remains one of the most challenging settings in gynecologic oncology, with limited treatment options and poor outcomes for patients," said Bhavana Pothuri, M.D., professor of Obstetrics/Gynecology and Medicine at NYU Grossman School of Medicine, NYU Langone Health and director of Clinical Trials Office at the Perlmutter Cancer Center. "The Breakthrough Therapy designation and preliminary clinical data for sofetabart mipitecan (搜索) across all levels of FRα (搜索) expression are encouraging and point to its potential as a meaningful treatment option for patients."
Novel Antibody-Drug Conjugate Technology
Sofetabart mipitecan (搜索) is composed of an Fc-silent, folate receptor alpha (搜索) (FRα (搜索)) specific humanized monoclonal antibody linked to exatecan, a topoisomerase I (搜索) inhibitor, via a proprietary cleavable polysarcosine linker (PSARlink™). The drug was designed to target FRα across all expression levels with improved therapeutic index.
FRα (搜索) is a cell-surface glycoprotein encoded by the gene FOLR1 (搜索) that binds to the essential nutrients folic acid and reduced folates, bringing them into cells to facilitate cell division and growth. FRα is overexpressed in many solid tumors such as ovarian, non-small cell lung, and colorectal cancers.
Promising Phase 1 Results Drive Designation
The FDA Breakthrough Therapy designation is based on encouraging preliminary results from the Phase 1a/b study. Lilly presented initial Phase 1 results at the 2025 ASCO Annual Meeting in June and updated data at the 2025 ESMO Congress in October, showing responses at all dose levels and across all FRα (搜索) expression levels, including in patients who progressed on prior mirvetuximab soravtansine.
The initial data also indicate a promising tolerability profile with low rates of interstitial lung disease, peripheral neuropathy, and alopecia, and no significant ocular toxicity—addressing key safety concerns associated with other treatments in this space.
Advancing to Phase 3 Development
Sofetabart mipitecan (搜索) recently advanced into the Phase 3 FRAmework-01 study (NCT07213804), a global trial investigating the treatment as a monotherapy in patients with platinum resistant ovarian cancer (搜索) (PROC), and in combination with bevacizumab in patients with platinum-sensitive ovarian cancer (PSOC). Lilly is conducting the FRAmework-01 study in partnership with the European Network for Gynaecological Oncological Trial groups (ENGOT - lead groups GINECO/NOGGO e.V.), the GOG Foundation (GOG), and the Asia-Pacific Gynecologic Oncology Trials Group (APGOT).
"We are pleased the FDA has granted Breakthrough Therapy designation for sofetabart mipitecan (搜索), reflecting the significant unmet need in platinum-resistant ovarian cancer (搜索) and the promising initial results shown in our Phase 1 study," said Jacob Van Naarden, executive vice president, and president of Lilly Oncology and head of corporate business development. "Building on compelling results generated to date, we've initiated our Phase 3 FRAmework-01 trial with the goal of bringing a potential therapeutic option to patients with advanced ovarian cancer (搜索), across all levels of folate receptor expression."
Broader Development Program
Beyond ovarian cancer (搜索), sofetabart mipitecan (搜索) is currently being studied in patients with other FRα (搜索)-expressing solid tumors through additional clinical trials (NCT06400472 and NCT07213804), potentially expanding its therapeutic applications across multiple cancer types where FRα overexpression is observed.